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1. INTRODUCTION {#mgg31030-sec-0005}
===============

Nasopharyngeal carcinoma (NPC) was one of the major invasive malignant neoplasms of the head and neck (Clifford, [1970](#mgg31030-bib-0005){ref-type="ref"}; Huang, [1990](#mgg31030-bib-0007){ref-type="ref"}; Yu, Ho, Henderson, & Armstrong, [1985](#mgg31030-bib-0032){ref-type="ref"}). It was especially prevalent in China, southeastern Asia, the natives of the Artic region, and the Arabs of North Africa and parts of the Middle East (Kamal & Samarrai, [1999](#mgg31030-bib-0008){ref-type="ref"}; Yu & Yuan, [2002](#mgg31030-bib-0033){ref-type="ref"}). In Indonesia, the mean prevalence was 6.2/100,000, with 13,000 yearly new NPC cases (Adham et al., [2012](#mgg31030-bib-0001){ref-type="ref"}). While in southern China it is much greater, with annual rates between 15 and 30 NPC cases per 100,000 (Kamran, Riaz, & Lee, [2015](#mgg31030-bib-0009){ref-type="ref"}). Radiotherapy alone or chemoradiotherapy, is an important component of the primary therapy of NPC for its highly radio‐sensitivity (Miao et al., [2019](#mgg31030-bib-0020){ref-type="ref"}; Zhan, Zhang, Wei, Fu, & Zheng, [2019](#mgg31030-bib-0035){ref-type="ref"}). However, predictors of the efficacy and toxicity response to radiotherapy of NPC have not been yet fully identified (Chen et al., [2019](#mgg31030-bib-0004){ref-type="ref"}; Kamran et al., [2015](#mgg31030-bib-0009){ref-type="ref"}; Miao et al., [2019](#mgg31030-bib-0020){ref-type="ref"}).

The discovery of suitable biomarkers is needed to predict efficacy and toxicity of radiotherapy in patients with NPC. Recently, single nucleotide polymorphisms (SNPs) of candidate genes have been to be associated with the outcomes and toxicity in patients accepting radiotherapy of many cancers, including lung cancer, NPC, prostate cancer, breast cancer, oropharyngeal cancer, thyroid cancer, and so on (Kerns et al., [2019](#mgg31030-bib-0010){ref-type="ref"}; Lewin et al., [2019](#mgg31030-bib-0014){ref-type="ref"}; Liu et al., [2018](#mgg31030-bib-0018){ref-type="ref"}; Tao et al., [2018](#mgg31030-bib-0024){ref-type="ref"}; Wang et al., [2017](#mgg31030-bib-0026){ref-type="ref"}; Wen et al., [2018](#mgg31030-bib-0027){ref-type="ref"}). Studies showed that autophagy played an important role in various stages of cancer development, progression, radio‐sensitivity and toxicity, including NPC (Liang et al., [2018](#mgg31030-bib-0016){ref-type="ref"}; Lin et al., [2014](#mgg31030-bib-0017){ref-type="ref"}; Qin et al., [2013](#mgg31030-bib-0023){ref-type="ref"}; Wen et al., [2018](#mgg31030-bib-0027){ref-type="ref"}; K. Xie et al., [2016](#mgg31030-bib-0028){ref-type="ref"}; Yang et al., [2018](#mgg31030-bib-0030){ref-type="ref"}; Yuan et al., [2017](#mgg31030-bib-0034){ref-type="ref"}; Zhu et al., [2018](#mgg31030-bib-0037){ref-type="ref"}). Autophagy could selectively target dysfunctional organelles, intracellular microbes, and pathogenic proteins, and deficiencies in these processes might lead to occurrence of cancers (Levine & Kroemer, [2019](#mgg31030-bib-0013){ref-type="ref"}). During this process, autophagy‐related genes (*ATG*) play an essential role in autophagy, and directly or indirectly accelerate cancer development and progression (Levine & Kroemer, [2019](#mgg31030-bib-0013){ref-type="ref"}; Tsuboyama et al., [2016](#mgg31030-bib-0025){ref-type="ref"}). The *ATG* family is a big family, and only a small part of the family members are currently known in humans (Klionsky, [2007](#mgg31030-bib-0011){ref-type="ref"}). Some potentially functional variants of *ATGs* have been identified to be associated with the development, progression, radio‐sensitivity and toxicity of other cancers, like lung cancer, hepatocellular carcinoma, prostate cancer, bladder cancer, breast cancer, and so on (Budak Diler & Aybuga, [2018](#mgg31030-bib-0003){ref-type="ref"}; Li et al., [2019](#mgg31030-bib-0015){ref-type="ref"}; Nikseresht et al., [2018](#mgg31030-bib-0022){ref-type="ref"}; Zhou et al., [2017](#mgg31030-bib-0036){ref-type="ref"}). Inspired by these findings, the present study was conducted to establish the relationships, if any, between potentially functional variants of *ATGs* and the efficacy of radiotherapy, as well as radiation‐induced toxicity reaction in NPC patients.

2. PATIENTS AND METHODS {#mgg31030-sec-0006}
=======================

2.1. Study populations {#mgg31030-sec-0007}
----------------------

The current study totally recruited 468 pathological diagnosed NPC patients treated with radiotherapy. The inclusion criteria was a first‐time diagnosis of NPC, no prior treatment of anticancer therapies, no severe disorders of lung, heart, liver, pancreas, or kidney diseases. At recruitment, each participant or family members signed the informed consent form and a 5 ml of blood sample from the patients was collected. Genetic DNA of all patients was extracted using Wizard Genomic DNA Purification Kit (Promega), and stored at −80°C for further evaluation. Questionnaires on patient demographics were collected prior to treatment. The present study\'s protocol was approved by the ethics committee of the Shengjing Hospital Affiliated to China Medical University.

2.2. Treatment efficacies and toxic reactions {#mgg31030-sec-0008}
---------------------------------------------

All the patients were treated with intensity modulated radiation‐therapy (IMRT), with a tumoricidal radiation dose of 66--70 Gy in 30--33 fractions for nasopharyngeal primary focus and the positive lymph nodes. All the patients underwent fluorodeoxyglucose‐positron emission tomography/computed tomography (FDG‐PET/CT) after treatment. Treatment efficacies at the primary tumor and lymph node were evaluated in line with the Response Criteria in Solid Tumors (PERCIST), which defined treatment efficacy as complete metabolic response (CMR). Radiation‐induced toxic reactions, including.

dermatitis, oral mucositis and myelosuppression, were evaluated according to the radiation toxicity grading criteria of the Radiation Therapy Oncology Group or European Organization for Research and Efficacy of Cancer (RTOG/EORTC). Patients were defined as "non‐sensitive or mildly radiosensitive" group (grade 0--2) and "highly radiosensitive" group (grade 3--4).

2.3. Selection of SNPs and genotyping {#mgg31030-sec-0009}
-------------------------------------

The selection of candidate SNPs were mainly based on study previously published by Wen et al. ([2018](#mgg31030-bib-0027){ref-type="ref"}). Eight of the nine functional SNPs \[*ATG2B* rs17784271 (3ʹUTR) and rs4900321 (3ʹUTR); *ATG10* rs10514231 (intron 2), and rs4703533 (the promoter region); *ATG12* rs26538 (the promoter region) and rs1058600 (3ʹUTR); *ATG16L2* rs1126205 (the promoter region) and rs10898880 (the promoter region)\], were included (MAF of rs6884232 in Chinese was 0). We also included two widely reported SNPs in *ATG10* gene, rs1864182 and rs1864183. This means totally 10 SNPs were included in this study. The genotyping was performed using the TaqMan methodology and read with the Sequence Detection Software on an ABI‐Prism 7,900 instrument according to the manufacturer\'s instructions (Applied Biosystems, Foster City, CA).

2.4. Statistical analysis {#mgg31030-sec-0010}
-------------------------

All statistical tests were two‐sided and a *p* value of .05 was considered significant, and all analyses were performed using SAS software version 9.2 (SAS Institute). Univariate logistic regression was performed to determine the association of the 10 SNPs with the efficacy at the primary tumor and lymph node, as well as the radiation‐induced toxicity reaction in NPC patients adjustment for age, gender, BMI, smoking, drinking, family history of cancer, EBV‐DNA, chemotherapy, and TNM stage.

3. RESULTS {#mgg31030-sec-0011}
==========

3.1. Population characteristics and clinical outcomes {#mgg31030-sec-0012}
-----------------------------------------------------

The baseline demographics and clinical profiles are presented in Table [1](#mgg31030-tbl-0001){ref-type="table"}. Totally 468 histopathological confirmed NPC cases, with a mean age of 49 (*SD* = 11), 319 male cases (68.2%), and a mean BMI of 23.1 (*SD* = 4.3), were included in this study. Among them, 128 (27.3%) were smokers, while 153 (32.7%) were drinkers. Plasma level of Epstein Barr virus (EBV) was detectable in 330 (70.5%) cases. Eighty‐two (17.5%) cases had family history of cancer, and 349 (74.6%) accepted chemotherapy meanwhile. The TNM stage distribution of all NPC patients were 61 (13.0%) for I or II, 284 (60.7%) for III, and 123 (26.3%) for IV, respectively. Overall, there were 95 (20.5%) and 80 (17.1%) patients who did not get CMR after radiotherapy at their primary tumors and lymph nodes, respectively. For the toxic reactions, 55 (11.8%), 242 (51.7%), 118 (25.2%) patients experienced grade 3--4 acute radiation‐induced dermatitis, oral mucositis, and myelosuppression, respectively.

###### 

NPC patient demographics and clinical characteristics

  Characteristics                                Patients (%)/values (*N* = 468)
  ---------------------------------------------- ---------------------------------
  Age                                            49 ± 11
  Gender                                         
  Male                                           319 (68.2%)
  Female                                         149 (31.8%)
  BMI                                            23.1 ± 4.3
  Smoking                                        
  Yes                                            128 (27.3%)
  No                                             340 (72.7%)
  Drinking                                       
  Yes                                            153 (32.7%)
  No                                             315 (67.3%)
  EBV‐DNA                                        
  Positive                                       330 (70.5%)
  Negative                                       138 (29.5%)
  Family history of cancer                       
  Yes                                            82 (17.5%)
  No                                             386 (82.5%)
  Chemotherapy                                   
  Yes                                            349 (74.6%)
  No                                             119 (25.4%)
  TNM stage                                      
  I, II                                          61 (13.0%)
  III                                            284 (60.7%)
  IV                                             123 (26.3%)
  Non‐CMR after radiotherapy                     
  Primary tumor                                  95 (20.5%)
  Lymph node                                     80 (17.1%)
  Grade 3--4 radiation‐induced toxic reactions   
  Dermatitis                                     55 (11.8%)
  Oral mucositis                                 242 (51.7%)
  Myelosuppression                               118 (25.2%)
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3.2. Associations between candidate SNPs and the efficacy of radiotherapy {#mgg31030-sec-0013}
-------------------------------------------------------------------------

Table [2](#mgg31030-tbl-0002){ref-type="table"} presents the associations between candidate SNPs and the efficacy of radiotherapy at the primary tumor and lymph node in NPC patients. We found *ATG10* rs10514231, rs1864183, and rs4703533, were significantly associated with worse efficacy of radiotherapy at both at the primary tumor (allelic model, for rs10514231: OR = 0.53, 95% CIs = 0.37--0.78, *p* = .001; for rs1864183: OR = 0.53, 95% CIs = 0.36--0.79, *p* = .002; for rs4703533: OR = 0.60, 95% CIs = 0.44--0.81, *p* = .001) and lymph node (allelic model, for rs10514231: OR = 0.52, 95% CIs = 0.35--0.78, *p* = .001; for rs1864183: OR = 0.48, 95% CIs = 0.32--0.73, *p* \< .001; for rs4703533: OR = 0.53, 95% CIs = 0.38--0.73, *p* \< .001). While *ATG16L2* rs10898880 was significantly associated with better efficacy of radiotherapy at both at the primary tumor (allelic model: OR = 1.84, 95% CIs = 1.32--2.56, *p* \< .001) and lymph node (allelic model: OR = 1.82, 95% CIs = 1.28--2.59, *p* = .001).

###### 

Association between candidate SNPs and the efficacy of radiotherapy at the primary tumor and lymph node in NPC patients

  Variants               Primary tumor   Lymph node                                                                    
  ---------------------- --------------- ------------ ------------------- ------------ ----- ---- -------------------- ------------
  *ATG2B* rs17784271                                                                                                   
  AA                     160             41           1.00 (Reference)                 162   39   1.00 (Reference)      
  AG                     152             35           1.16 (0.6--2.22)    .661         158   29   1.36 (0.77--2.42)    .290
  GG                     61              19           0.88 (0.56--1.39)   .583         68    12   1.48 (0.7--3.15)     .307
  G versus A                                          0.98 (0.89--1.08)   .721                    1.31 (0.87--1.95)    .194
  *ATG2B* rs4900321                                                                                                    
  AA                     246             68           1.00 (Reference)                 255   59   1.00 (Reference)      
  AT                     103             23           1.26 (0.69--2.3)    .452         107   19   1.32 (0.71--2.46)    .382
  TT                     24              4            1.68 (0.55--5.09)   .359         26    2    2.99 (0.76--11.69)   .116
  T versus A                                          1.33 (0.83--2.12)   .234                    1.56 (0.95--2.54)    .078
  *ATG10* rs10514231                                                                                                   
  AA                     311             68           1.00 (Reference)                 322   57   1.00 (Reference)      
  AG                     40              16           0.56 (0.32--0.99)   **.045**     43    13   0.6 (0.33--1.09)     .095
  GG                     22              11           0.47 (0.23--0.93)   **.029**     23    10   0.43 (0.21--0.88)    **.021**
  G versus A                                          0.53 (0.37--0.78)   **.001**                0.52 (0.35--0.78)    **.001**
  *ATG10* rs1864183                                                                                                    
  AA                     311             68           1.00 (Reference)                 324   55   1.00 (Reference)      
  AG                     50              20           0.56 (0.34--0.94)   **.028**     51    19   0.47 (0.28--0.8)     **.005**
  GG                     12              7            0.41 (0.17--0.97)   **.042**     13    6    0.40 (0.16--0.99)    **.049**
  G versus A                                          0.53 (0.36--0.79)   **.002**                0.48 (0.32--0.73)    **\<.001**
  *ATG10* rs1864182                                                                                                    
  AA                     316             77           1.00 (Reference)                 331   62   1.00 (Reference)      
  AC                     47              14           0.86 (0.53--1.41)   .552         46    15   0.61 (0.34--1.06)    .081
  CC                     10              4            0.63 (0.22--1.76)   .376         11    3    0.71 (0.23--2.13)    .538
  C versus A                                          0.79 (0.52--1.19)   .261                    0.66 (0.42--1.04)    .076
  *ATG10* rs4703533                                                                                                    
  CC                     231             45           1.00 (Reference)                 242   34   1.00 (Reference)      
  CG                     118             36           0.66 (0.43--1.01)   .053         120   34   0.51 (0.32--0.81)    **.005**
  GG                     24              13           0.36 (0.19--0.7)    **.003**     26    11   0.33 (0.17--0.67)    **.002**
  G versus C                                          0.6 (0.44--0.81)    **.001**                0.53 (0.38--0.73)    **\<.001**
  *ATG12* rs1058600                                                                                                    
  CC                     141             37           1.00 (Reference)                 148   30   1.00 (Reference)      
  CT                     172             43           1.08 (0.41--2.82)   .875         178   37   1.00 (0.99--1.02)    .882
  TT                     60              15           1.1 (0.36--3.38)    .874         62    13   1.01 (0.82--1.25)    .932
  T versus C                                          1.07 (0.52--2.22)   .853                    1.02 (0.75--1.39)    .905
  *ATG12* rs26538                                                                                                      
  CC                     134             30           1.00 (Reference)                 139   25   1.00 (Reference)      
  CT                     192             51           0.86 (0.59--1.26)   .449         200   43   0.86 (0.57--1.29)    .457
  TT                     47              14           0.79 (0.44--1.41)   .421         49    12   0.77 (0.41--1.45)    .414
  T versus C                                          0.91 (0.73--1.13)   .388                    0.9 (0.71--1.14)     .386
  *ATG16L2* rs1126205                                                                                                  
  GG                     113             27           1.00 (Reference)                 119   21   1.00 (Reference)      
  GT                     208             54           0.97 (0.78--1.2)    .780         216   46   0.88 (0.58--1.32)    .530
  TT                     52              14           0.97 (0.72--1.32)   .844         53    13   0.79 (0.42--1.48)    .465
  T versus G                                          1.00 (0.97--1.03)   .820                    0.92 (0.74--1.15)    .470
  *ATG16L2* rs10898880                                                                                                 
  AA                     85              36           1.00 (Reference)                 91    30   1.00 (Reference)      
  AC                     189             46           1.81 (1.08--3.02)   **.023**     195   41   1.63 (0.94--2.83)    **.081**
  CC                     99              13           3.35 (1.72--6.53)   **\<.001**   102   10   3.5 (1.69--7.25)     **.001**
  C versus A                                          1.84 (1.32--2.56)   **\<.001**              1.82 (1.28--2.59)    **.001**

*p* value in bold means statistically significant.

Age, gender, BMI, smoking, drinking, family history of cancer, EBV‐DNA, chemotherapy, and TNM stage
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3.3. Associations between the candidate SNPs and grade 3--4 radiation‐induced toxic reactions {#mgg31030-sec-0014}
---------------------------------------------------------------------------------------------

Tables [3](#mgg31030-tbl-0003){ref-type="table"} and [4](#mgg31030-tbl-0004){ref-type="table"} presents the associations between the candidate SNPs and grade 3--4 radiation‐induced oral mucositis and myelosuppression, respectively. We found *ATG10* rs10514231 and *ATG16L2* rs10898880 were significantly associated with the occurrence of grade 3--4 oral mucositis (allelic model, for rs10514231: OR = 1.95, 95% CIs = 1.31--2.9, *p* = .001; for rs10898880: OR = 1.56, 95% CIs = 1.19--2.04, *p* = .001) and grade 3--4 myelosuppression (allelic model, for rs10514231: OR = 2.08, 95% CIs = 1.39--3.09, *p* \< .001; for rs10898880: OR = 1.51, 95% CIs = 1.1--2.06, *p* = .010). We did not find significant associations for grade 3--4 radiation‐induced dermatitis, due to the small sample size.

###### 

Association between candidate SNPs and Grade 3--4 radiation‐induced oral mucositis

  Variants               Grade 3--4   Grade 0--2   OR (95% CIs)[\*](#mgg31030-note-0004){ref-type="fn"}   *p* value
  ---------------------- ------------ ------------ ------------------------------------------------------ -----------
  *ATG2B* rs17784271                                                                                      
  AA                     98           103          1.00 (Reference)                                        
  AG                     100          87           1.26 (0.79--1.99)                                      .329
  GG                     44           36           1.36 (0.77--2.4)                                       .295
  G versus A                                       1.23 (0.89--1.68)                                      .205
  *ATG2B* rs4900321                                                                                       
  AA                     158          156          1.00 (Reference)                                        
  AT                     67           59           1.16 (0.67--1.98)                                      .600
  TT                     17           11           1.57 (0.69--3.56)                                      .280
  T versus A                                       1.25 (0.86--1.82)                                      .252
  *ATG10* rs10514231                                                                                      
  CC                     185          194          1.00 (Reference)                                        
  CT                     35           21           1.8 (1.01--3.23)                                       **.047**
  TT                     22           11           2.23 (1.06--4.69)                                      **.035**
  T versus C                                       1.95 (1.31--2.9)                                       **.001**
  *ATG10* rs1864183                                                                                       
  AA                     197          182          1.00 (Reference)                                        
  AG                     35           35           0.96 (0.74--1.24)                                      .733
  GG                     10           9            1.1 (0.25--4.86)                                       .898
  G versus A                                       1.01 (0.86--1.19)                                      .887
  *ATG10* rs1864182                                                                                       
  AA                     204          189          1.00 (Reference)                                        
  AC                     31           30           1 (0.98--1.02)                                         .886
  CC                     7            7            0.96 (0.57--1.62)                                      .875
  C versus A                                       0.99 (0.91--1.07)                                      .819
  *ATG10* rs4703533                                                                                       
  CC                     143          133          1.00 (Reference)                                        
  CG                     82           72           1.1 (0.57--2.12)                                       .785
  GG                     17           20           0.81 (0.46--1.4)                                       .442
  G versus C                                       0.98 (0.89--1.08)                                      .681
  *ATG12* rs1058600                                                                                       
  CC                     92           86           1.00 (Reference)                                        
  CT                     111          104          1.03 (0.17--6.19)                                      .972
  TT                     39           36           1.05 (0.15--7.42)                                      .957
  T versus C                                       1.04 (0.08--13.08)                                     .973
  *ATG12* rs26538                                                                                         
  CC                     85           79           1.00 (Reference)                                        
  CT                     125          118          1.02 (0.74--1.41)                                      .913
  TT                     32           29           1.07 (0.28--4.09)                                      .922
  T versus C                                       1.04 (0.08--13.08)                                     .973
  *ATG16L2* rs1126205                                                                                     
  GG                     72           68           1.00 (Reference)                                        
  GT                     136          126          1.07 (0.38--2.95)                                      .902
  TT                     34           32           1.07 (0.25--4.58)                                      .932
  T versus G                                       1.05 (0.38--2.91)                                      .920
  *ATG16L2* rs10898880                                                                                    
  AA                     47           74           1.00 (Reference)                                        
  AC                     129          106          1.99 (1.27--3.12)                                      **.003**
  CC                     66           46           2.35 (1.4--3.95)                                       **.001**
  C versus A                                       1.56 (1.19--2.04)                                      **.001**

*p* value in bold means statistically significant.

Age, gender, BMI, smoking, drinking, family history of cancer, EBV‐DNA, chemotherapy, and TNM stage.
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###### 

Association between candidate SNPs and Grade 3--4 radiation‐induced myelosuppression

  Variants               Grade 3--4   Grade 0--2   OR (95% CIs)[\*](#mgg31030-note-0006){ref-type="fn"}   *p* value
  ---------------------- ------------ ------------ ------------------------------------------------------ ------------
  *ATG2B* rs17784271                                                                                      
  AA                     47           154          1.00 (Reference)                                        
  AG                     49           138          1.21 (0.7--2.1)                                        .500
  GG                     22           58           1.3 (0.67--2.52)                                       .429
  G versus A                                       1.19 (0.82--1.73)                                      .353
  *ATG2B* rs4900321                                                                                       
  AA                     76           238          1.00 (Reference)                                        
  AT                     33           93           1.15 (0.61--2.16)                                      .665
  TT                     9            19           1.53 (0.64--3.66)                                      .336
  T versus A                                       1.24 (0.81--1.89)                                      .321
  *ATG10* rs10514231                                                                                      
  CC                     85           294          1.00 (Reference)                                        
  CT                     20           36           1.99 (1.1--3.61)                                       **.024**
  TT                     13           20           2.37 (1.15--4.88)                                      **.020**
  T versus C                                       2.08 (1.39--3.09)                                      **\<.001**
  *ATG10* rs1864183                                                                                       
  AA                     95           284          1.00 (Reference)                                        
  AG                     18           52           1.07 (0.3--3.81)                                       .914
  GG                     5            14           1.13 (0.26--4.87)                                      .866
  G versus A                                       1.09 (0.49--2.42)                                      .831
  *ATG10* rs1864182                                                                                       
  AA                     99           294          1.00 (Reference)                                        
  AC                     15           46           1.01 (0.8--1.28)                                       .926
  CC                     4            10           1.23 (0.31--4.93)                                      .769
  C versus A                                       1.08 (0.41--2.84)                                      .876
  *ATG10* rs4703533                                                                                       
  CC                     73           203          1.00 (Reference)                                        
  CG                     37           117          0.91 (0.67--1.24)                                      .553
  GG                     8            29           0.79 (0.4--1.54)                                       .485
  G versus C                                       0.89 (0.7--1.14)                                       .376
  *ATG12* rs1058600                                                                                       
  CC                     45           133          1.00 (Reference)                                        
  CT                     53           161          1.01 (0.84--1.22)                                      .902
  TT                     20           56           1.1 (0.4--3.01)                                        .856
  T versus C                                       1.06 (0.41--2.73)                                      .908
  *ATG12* rs26538                                                                                         
  CC                     42           122          1.00 (Reference)                                        
  CT                     61           182          1.01 (0.89--1.14)                                      .891
  TT                     15           46           0.99 (0.84--1.16)                                      .874
  T versus C                                       1.01 (0.86--1.2)                                       .866
  *ATG16L2* rs1126205                                                                                     
  GG                     39           101          1.00 (Reference)                                        
  GT                     64           198          0.87 (0.62--1.23)                                      .440
  TT                     15           51           0.8 (0.46--1.4)                                        .436
  T versus G                                       0.92 (0.76--1.12)                                      .413
  *ATG16L2* rs10898880                                                                                    
  AA                     20           101          1.00 (Reference)                                        
  AC                     64           171          1.97 (1.12--3.44)                                      **.018**
  CC                     34           78           2.29 (1.23--4.25)                                      **.009**
  C versus A                                       1.51 (1.1--2.06)                                       **.010**

*p* value in bold means statistically significant.

Age, gender, BMI, smoking, drinking, family history of cancer, EBV‐DNA, chemotherapy, and TNM stage.
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4. DISCUSSION {#mgg31030-sec-0015}
=============

In present study, we investigated the associations of 10 potentially functional SNPs in *ATG2B, ATG10, ATG12*, and *ATG16L2* with the efficacy and toxicity of radiotherapy in 468 NPC patients. We found *ATG10* rs10514231, rs1864183, and rs4703533 were significantly associated with worse efficacy of radiotherapy at both at the primary tumor and lymph node, while *ATG16L2* rs10898880 was significantly associated with better efficacy of radiotherapy at both at the primary tumor and lymph node. Besides, we also found *ATG10* rs10514231 and *ATG16L2* rs10898880 were significantly associated with the occurrence of grade 3--4 oral mucositis and myelosuppression. These results suggest that potentially functional variants of ATGs might be useful biomarkers for predicting efficacy and toxicity of radiotherapy in NPC patients, once these results were validated by additional investigations.

With the rapid development of radio‐genomics, many studies have presented significant associations between genetic variants of candidate gene with the efficacy and toxicity of radiotherapy in NPC patients (Guo et al., [2017](#mgg31030-bib-0006){ref-type="ref"}; Ma et al., [2017](#mgg31030-bib-0019){ref-type="ref"}; Xie et al., [2014](#mgg31030-bib-0029){ref-type="ref"}; Yu et al., [2016](#mgg31030-bib-0031){ref-type="ref"}). Xie et al. ([2014](#mgg31030-bib-0029){ref-type="ref"}) found that the *p53* codon 72 polymorphism could be an independent prognostic marker for locoregionally advanced NPC. Guo et al. ([2017](#mgg31030-bib-0006){ref-type="ref"}) reported that *CDKN2A* rs3088440 was significantly related with a poorer treatment efficacy on the primary tumor and cervical lymph node after radiotherapy, and also with a decreased risk of grade 3--4 acute radiation‐induced myelosuppression. Ma et al. ([2017](#mgg31030-bib-0019){ref-type="ref"}) found that polymorphisms in angiogenesis related genes could contribute to clinical outcomes of radiotherapy in NPC patients. Yu et al. ([2016](#mgg31030-bib-0031){ref-type="ref"}) detected that *CTNNB1* rs1880481 and rs3864004, and *GSK3β* rs3755557 were significantly associated with poorer efficacy of radiotherapy in NPC patients, while *GSK3β* rs375557 and *APC* rs454886 were correlated with acute grade 3--4 radiation‐induced dermatitis and oral mucositis, respectively. These findings above revealed that genetic variants could potentially work as the indicator of efficacy and toxicity of radiotherapy in NPC patients.

Emerging evidence has revealed that autophagy process, which degrades intracellular components through the lysosomal machinery, plays an essential role in the process of cancer development and progression (Avalos et al., [2014](#mgg31030-bib-0002){ref-type="ref"}; Mizushima, Levine, Cuervo, & Klionsky, [2008](#mgg31030-bib-0021){ref-type="ref"}), while *ATGs* could control autophagic formation, and directly or indirectly accelerate cancer development and progression (Levine & Kroemer, [2008](#mgg31030-bib-0012){ref-type="ref"}). Xie et al. ([2016](#mgg31030-bib-0028){ref-type="ref"}) identified that *ATG10* rs10514231, rs1864182 and rs1864183 were associated with poor lung cancer survival and positively correlated with *ATG10* expression. In current study, we also found *ATG10* rs10514231, rs1864183, and rs4703533 were significantly associated with worse efficacy of radiotherapy at both primary tumor and lymph node. Qin et al. ([2013](#mgg31030-bib-0023){ref-type="ref"}) reported that *ATG10* rs1864182 and rs10514231 were significantly associated with a decreased risk of breast cancer in Chinese population. Yuan et al. ([2017](#mgg31030-bib-0034){ref-type="ref"}) also revealed that genetic variations in *ATGs* were significantly associated with clinical outcomes of advanced lung adenocarcinoma treated with gefitinib. Recently, Wen et al. ([2018](#mgg31030-bib-0027){ref-type="ref"}) found *ATG16L2* rs10898880 contributed to a better prognosis of patients with non‐small cell lung cancer (NSCLC) after definitive radiotherapy, and a greater risk of developing severe radiation pneumonitis. This results were similar to the findings in current study, which revealed that *ATG16L2* rs10898880 was significantly associated with better efficacy of radiotherapy at both at the primary tumor and lymph node, and had a greater risk of developing grade 3--4 oral mucositis and myelosuppression.

5. CONCLUSIONS {#mgg31030-sec-0016}
==============

Conclusively, we identified *ATG10* rs10514231, rs1864183, rs4703533, and *ATG16L2* rs10898880 could contribute to the efficacy and toxicity of radiotherapy in NPC patients. Further investigation of the underlying molecular mechanisms to explain how these polymorphisms affect response to radiotherapy and prospective clinical trials in NPC patients are needed to validate our results.
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